Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27787 | 0.92 | HPGDS (1.00) | HPGDSCRBN | |
| SCHEMBL27589 | 0.91 | HPGDS (1.00) | HPGDSCRBN | |
| SCHEMBL23000070 | 0.90 | HPGDS (0.81) | HPGDSCRBN | |
| SCHEMBL28492 | 0.87 | HPGDS (0.81) | HPGDSCRBN | |
| SCHEMBL28315 | 0.86 | HPGDS (1.00) | HPGDSCRBN | |
| SCHEMBL28755 | 0.85 | HPGDS (1.00) | HPGDS | |
| SCHEMBL9998846 | 0.85 | HPGDS (1.00) | HPGDSCRBN | |
| SCHEMBL27841 | 0.85 | HPGDS (1.00) | HPGDSCRBN | |
| SCHEMBL28314 | 0.84 | HPGDS (0.73) | HPGDSCRBN | |
| SCHEMBL23017395 | 0.81 | HPGDS (0.73) | HPGDSCRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4482481-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | SOM INNOVATION BIOTECH S A (ES) | 2025-11-12 | — | — | EP | claimed |
| US-20250152567-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2025-05-15 | — | — | US | claimed |
| EP-4482481-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | Som Innovation Biotech, S.L. (ES) | 2025-01-01 | — | — | EP | claimed |
| EP-3782648-B1 | PROSTAGLANDIN D2 PRODUCTION INHIBITORS AS PREVENTATIVE AND THERAPEUTIC AGENTS FOR SARCOPENIA | NATIONAL UNIV CORPORATION TOKYO UNIV OF AGRICULTURE AND TECHNOLOGY (JP) | 2024-09-18 | — | — | EP | claimed |
| US-11883410-B2 | Preventative and therapeutic agents for sarcopenia | NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLGY (JP) | 2024-01-30 | — | — | US | claimed |
| WO-2023156645-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | SOM INNOVATION BIOTECH, S.A. (ES) | 2023-08-24 | — | — | WO | claimed |
| EP-4230196-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | Som Innovation Biotech, S.A. (ES) | 2023-08-23 | — | — | EP | claimed |
| US-20210161908-A1 | PREVENTATIVE AND THERAPEUTIC AGENTS FOR SARCOPENIA | NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY (JP) | 2021-06-03 | — | — | US | claimed |
| EP-3782648-A1 | PREVENTATIVE AND THERAPEUTIC AGENTS FOR SARCOPENIA | National University Corporation Tokyo University of Agriculture and Technology (JP) | 2021-02-24 | — | — | EP | claimed |
| EP-4482481-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | SOM INNOVATION BIOTECH S A (ES) | 2025-11-12 | — | — | EP | disclosed |
| WO-2025104229-A1 | HEMATOPOIETIC PROSTAGLANDIN SYNTHASE (HPGDS) INHIBITION FOR TREATING CANCER | VIB VZW (BE) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025104238-A1 | INHIBITION OF PROSTAGLANDIN D2 RECEPTOR 2 AS MEANS FOR TREATING CANCER | VIB VZW (BE) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025104233-A1 | INHIBITION OF PROSTAGLANDIN D2 RECEPTOR 1 AS MEANS FOR TREATING CANCER | VIB VZW (BE) | 2025-05-22 | — | — | WO | disclosed |
| US-20250152567-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2025-05-15 | — | — | US | disclosed |
| US-20210161908-A1 | PREVENTATIVE AND THERAPEUTIC AGENTS FOR SARCOPENIA | NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY (JP) | 2021-06-03 | — | — | US | disclosed |
| WO-2021066136-A1 | THERAPEUTIC AGENT FOR MUSCULAR DYSTROPHY | 国立大学法人東京大学 | 2021-04-08 | — | — | WO | disclosed |
| EP-3782648-A1 | PREVENTATIVE AND THERAPEUTIC AGENTS FOR SARCOPENIA | National University Corporation Tokyo University of Agriculture and Technology (JP) | 2021-02-24 | — | — | EP | disclosed |
| WO-2019203296-A1 | PREVENTATIVE AND THERAPEUTIC AGENTS FOR SARCOPENIA | 国立大学法人東京農工大学 | 2019-10-24 | — | — | WO | disclosed |
| EP-3351542-A1 | NEW CRYSTAL OF PIPERAZINE COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-07-25 | — | — | EP | disclosed |
| EP-2407466-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | Taiho Pharmaceutical Co., Ltd. (JP) | 2012-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152567-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | MTPN, UTRN, TTN | HPGDS 4772/4885CRBN 313/4885 |
| US-11883410-B2 | Preventative and therapeutic agents for sarcopenia | CPT1B, TNNC1, MTPN | HPGDS 32/4885CRBN 3896/4885 |
| US-20210161908-A1 | PREVENTATIVE AND THERAPEUTIC AGENTS FOR SARCOPENIA | CPT1B, TNNC1, MTPN | HPGDS 32/4885CRBN 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.